Simon P Kim
Overview
Explore the profile of Simon P Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
2691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiesen B, Flaig T, Gershman B, Konety B, Warren A, Kuna E, et al.
Adv Urol
. 2024 Dec;
2024:8871425.
PMID: 39735345
Although clinical trials should be accessible to all patients, persistent racial and ethnic disparities in clinical trial enrollment exist. Herein, we examine racial disparities in clinical trial enrollment among prostate...
2.
Eule C, Warren A, Kuna E, Robin T, Gershman B, Kim S, et al.
Prostate Cancer Prostatic Dis
. 2024 Nov;
PMID: 39572637
Background: Small cell prostate cancer (SCPC) is a rare, aggressive disease with limited clinical data to guide treatment. In this retrospective study, we evaluated clinical, treatment, and outcomes data for...
3.
Ballon-Landa E, Hannemann A, Gershman B, Rodrigues Pessoa R, Olson B, Clark P, et al.
Urol Oncol
. 2024 Nov;
PMID: 39492009
Objectives: To increase the population-level understanding of upper tract imaging evaluation during risk-based hematuria assessment. Using a national, privately-insured cohort, we evaluated the rates of imaging and the diagnostic yield...
4.
Eule C, Kuna E, Robin T, Gershman B, Flaig T, Kim S
Urol Oncol
. 2024 Aug;
42(12):447.e17-447.e24.
PMID: 39191549
Background: In metastatic hormone-sensitive prostate cancer (mHSPC), androgen deprivation therapy and standard of care treatment intensification with docetaxel and/or an androgen receptor signaling inhibitor (ARSI) are associated with improved survival...
5.
Eule C, Warren A, Kuna E, Callihan E, Kim S, Flaig T
Urology
. 2024 Apr;
188:118-124.
PMID: 38685388
Objective: To determine whether neoadjuvant gemcitabine and cisplatin (GC) vs dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical cystectomy improves overall survival (OS), progression-free survival (PFS), and pathologic complete...
6.
Hannemann A, Rodrigues Pessoa R, Flaig T, Kuna E, Warren A, Robin T, et al.
Urol Oncol
. 2024 Apr;
42(8):246.e1-246.e5.
PMID: 38679529
Introduction: To investigate the actual cost of hematuria evaluation using nationally representative claims data, given that the workup for hematuria burdens the healthcare system with significant associated costs. We hypothesized...
7.
Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, et al.
Prostate Cancer Prostatic Dis
. 2024 Mar;
PMID: 38555410
Background: Although active surveillance is the preferred management for low-risk prostate cancer (PCa), some men remain at risk of overtreatment with definitive local therapy. We hypothesized that baseline characteristics may...
8.
Kiani K, Kim S, Rodrigues Pessoa R, Gershman B, Gonzalez C, Molina E, et al.
Urol Pract
. 2023 Nov;
11(1):117-122.
PMID: 37914379
Introduction: Prostate needle biopsy (PNBx) is essential for prostate cancer diagnosis, yet it is not without risks. We sought to assess patients who underwent PNBx using a claims-based frailty index...
9.
Yang J, Huynh V, Leonard L, Kovar A, Bronsert M, Ludwigson A, et al.
Breast Care (Basel)
. 2023 Oct;
18(4):240-248.
PMID: 37900555
Introduction: Receiving a new breast cancer diagnosis can cause anxiety and distress, which can lead to psychologic morbidity, decreased treatment adherence, and worse clinical outcomes. Understanding sources of distress is...
10.